• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PainReform Ltd.

    4/3/25 4:30:32 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    6-K 1 zk2532972.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 6-K

    Report of Foreign Private Issuer
     
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934
     
    For the month of April 2025
     
    Commission File Number: 001-40614
     
    PainReform LTD.
    (Translation of registrant’s name into English)
     
    65 Yigal Alon St., Tel Aviv 6744316
    Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
     
    Form 20-F ☒          Form 40-F ☐


    On April 3, 2025, PainReform Ltd. (the “Company”) convened an Extraordinary General Meeting of Shareholders (the “Extraordinary General Meeting”). However, the Extraordinary General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Extraordinary General Meeting will be reconvened on Thursday, April 10, 2025 at 3:00 p.m., Israel time, at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel.
     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    PAINREFORM LTD.
     
     
    Date: April 3, 2025
    /s/ Ehud Geller
     
    Ehud Geller
    Interim Chief Executive Officer


    Get the next $PRFX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

      As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ:PRFX). According to the agreement, which was completed in March 2025, Blade Ranger received a package of securities that included, among o

      5/27/25 12:12:00 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The project will utilize PainReform's proprietary DeepSolar™ platform, an AI-powered optimization solution designed to enhance operational efficiency and energy yield at utility-scale solar facilities. The pilot will be conducted at Econergy's 92-megawatt (MW) photovoltaic plant in Parau, Romania—one of the country's largest operational solar projects. This initiative marks the first phase of a broader collaboration between PainReform and Econergy, designed to demo

      5/7/25 4:30:00 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

      TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven software solutions designed to optimize solar energy usage in residential and utility-scale solar power plants. This strategic expansion marks an important milestone in PainReform's long-term diversification strategy, aimed at tapping into high-growth, tech-enabled markets. With global solar capacity a

      4/10/25 8:30:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    See more
    • PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

      HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

      3/18/21 9:15:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

      HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

      1/6/21 8:30:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

      SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

      11/14/24 4:25:42 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

      SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

      11/13/24 11:18:32 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

      SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

      8/29/24 4:00:27 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    SEC Filings

    See more
    • SEC Form EFFECT filed by PainReform Ltd.

      EFFECT - PAINREFORM LTD. (0001801834) (Filer)

      5/12/25 12:15:17 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by PainReform Ltd.

      424B3 - PAINREFORM LTD. (0001801834) (Filer)

      5/9/25 4:39:05 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PainReform Ltd.

      6-K - PAINREFORM LTD. (0001801834) (Filer)

      5/7/25 4:41:40 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care